Posting of Annual Report & Accounts

ReNeuron Group plc

16 June 2023

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Posting of Annual Report & Accounts

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2023 has today been sent to shareholders and is available to download on the Company's website here: https://www.reneuron.com/investors/financial-reports/

ENDS

Enquiries:

ReNeuron	www.reneuron.com/investors
Iain Ross, Executive Chairman	Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser and Broker)	[phone]
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

END